Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Gastroenterology. 2020 Dec 14;160(4):1373–1383.e6. doi: 10.1053/j.gastro.2020.11.052

Figure 4. Classifier performance of CA19-9 in Test Set #1 and Test Set #2.

Figure 4.

A-B) AUC (95% CI) and sensitivity (95% CI) at 99% specificity of CA19-9 for distinguishing resectable PDAC cases (n=99) from matched healthy controls (n=100) (A) or subjects with chronic pancreatitis (n=50) (B). C) AUC (95% CI) and sensitivity at 99% specificity of CA19-9 for distinguishing resectable PDAC cases (8 PDAC and 22 IPMN with an associated invasive ductal adenocarcinoma) from subjects harboring benign IPMN (n=125). D-E) AUC (95% CI) and sensitivity (95% CI) at 99% specificity of CA19-9 for distinguishing PDAC (n=8) (D) or Invasive IPMN (n=22) (E) from subjects harboring benign IPMN (n=125).